News coverage about Hutchison China MediTech (NASDAQ:HCM) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Hutchison China MediTech earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.4276309210777 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

HCM has been the subject of a number of analyst reports. BidaskClub upgraded Hutchison China MediTech from a “hold” rating to a “buy” rating in a research note on Tuesday, October 31st. Canaccord Genuity lifted their price target on Hutchison China MediTech to $38.00 and gave the company a “buy” rating in a research note on Monday, October 16th.

Shares of Hutchison China MediTech (NASDAQ:HCM) traded up $0.90 during midday trading on Friday, hitting $39.42. The stock had a trading volume of 76,478 shares, compared to its average volume of 86,134. Hutchison China MediTech has a 12-month low of $12.62 and a 12-month high of $40.26. The company has a current ratio of 1.84, a quick ratio of 1.73 and a debt-to-equity ratio of 0.09.

WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Hutchison China MediTech (HCM) Stock Price” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at

About Hutchison China MediTech

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Insider Buying and Selling by Quarter for Hutchison China MediTech (NASDAQ:HCM)

Receive News & Ratings for Hutchison China MediTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech and related companies with Analyst Ratings Network's FREE daily email newsletter.